Organovo

Focus: Organovo is a San Diego-based biotech company specializing in bioprinter technology for tissue engineering and drug development applications. The company operates as a public entity in the biotechnology sector with a focus on regenerative medicine platforms.

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Organovo

AI assessmentNot Hiring

No open roles listed right now. Follow Organovo to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Recent News · Organovo(1)

FinancialSEC 8-K

Feb 26, 2026

8-K Filing: Atrium Therapeutics, Inc. (CIK 0002093101) — EX-99.1

EX-99.1

Open Jobs (0)

Help build intelligence for Organovo

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneer in 3D bioprinting technology with potential to transform drug development and tissue engineering — early-stage opportunity to shape an emerging field
Public company status provides stability and potential equity upside compared to early-stage private ventures
Access to cutting-edge research with 5 peer-reviewed publications demonstrating scientific credibility and output

Watch Out For

Zero active clinical trials reported and no marketed products indicate pre-commercialization stage with extended timeline to revenue generation and returns
Currently zero open job postings suggests minimal hiring activity, potentially indicating restructuring or capital constraints
Limited public financial data and unclear commercialization strategy create visibility risk around company trajectory and long-term viability

Generated by Claude from Organovo's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Publications: 23 in PubMed

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo